Wall Street brokerages expect that Voyager Therapeutics (NASDAQ:VYGR) will post earnings per share (EPS) of ($0.62) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Voyager Therapeutics’ earnings, with estimates ranging from ($0.76) to ($0.47). Voyager Therapeutics posted earnings of ($0.73) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The business is expected to issue its next quarterly earnings results on Tuesday, August 14th.
According to Zacks, analysts expect that Voyager Therapeutics will report full year earnings of ($2.71) per share for the current fiscal year, with EPS estimates ranging from ($3.26) to ($2.10). For the next year, analysts anticipate that the business will report earnings of ($3.12) per share, with EPS estimates ranging from ($4.38) to ($2.38). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Thursday, May 10th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.52). The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $4.00 million. Voyager Therapeutics had a negative return on equity of 69.92% and a negative net margin of 768.99%.
A number of equities research analysts have issued reports on VYGR shares. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Friday, March 16th. BidaskClub lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 19th. Wedbush increased their target price on shares of Voyager Therapeutics from $22.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday, February 21st. Canaccord Genuity set a $35.00 target price on shares of Voyager Therapeutics and gave the stock a “buy” rating in a report on Wednesday, March 14th. Finally, BTIG Research reiterated a “buy” rating and set a $32.00 target price on shares of Voyager Therapeutics in a report on Sunday, March 11th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Voyager Therapeutics has a consensus rating of “Buy” and an average target price of $29.73.
In other news, CFO Jane Henderson sold 17,316 shares of the firm’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $22.11, for a total value of $382,856.76. Following the sale, the chief financial officer now directly owns 15,416 shares in the company, valued at approximately $340,847.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bernard Ravina sold 2,451 shares of the firm’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $25.16, for a total transaction of $61,667.16. The disclosure for this sale can be found here. Insiders sold a total of 64,457 shares of company stock worth $1,529,552 over the last 90 days. Company insiders own 33.60% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in VYGR. BlackRock Inc. raised its holdings in shares of Voyager Therapeutics by 73.9% in the 4th quarter. BlackRock Inc. now owns 1,210,763 shares of the company’s stock valued at $20,099,000 after purchasing an additional 514,345 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of Voyager Therapeutics by 290.5% in the 4th quarter. Farallon Capital Management LLC now owns 654,812 shares of the company’s stock valued at $10,870,000 after purchasing an additional 487,147 shares in the last quarter. BB Biotech AG raised its holdings in shares of Voyager Therapeutics by 29.4% in the 1st quarter. BB Biotech AG now owns 1,992,641 shares of the company’s stock valued at $37,442,000 after purchasing an additional 453,121 shares in the last quarter. Millennium Management LLC raised its stake in Voyager Therapeutics by 124.0% during the 1st quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock worth $11,613,000 after acquiring an additional 342,148 shares in the last quarter. Finally, AXA acquired a new stake in Voyager Therapeutics during the 4th quarter worth $5,591,000. Institutional investors and hedge funds own 84.03% of the company’s stock.
Voyager Therapeutics opened at $18.58 on Friday, MarketBeat Ratings reports. The company has a market cap of $606.34 million, a price-to-earnings ratio of -7.04 and a beta of 2.98. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $31.91.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.